Article
Oncology
J. S. Frenel, J. W. Kim, N. Aryal, R. Asher, D. Berton, L. Vidal, P. Pautier, J. A. Ledermann, R. T. Penson, A. M. Oza, J. Korach, T. Huzarski, S. Pignata, N. Colombo, T. W. Park-Simon, K. Tamura, G. S. Sonke, A. E. Freimund, C. K. Lee, E. Pujade-Lauraine
Summary: In the SOLO2 trial, maintenance olaparib showed significant improvement in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation. However, the efficacy of subsequent chemotherapy after olaparib treatment is still unknown.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
S. I. Labidi-Galy, M. Rodrigues, J. L. Sandoval, J. E. Kurtz, F. Heitz, A. M. Mosconi, I. Romero, U. Denison, S. Nagao, I. Vergote, G. Parma, T. J. Nottrup, E. Rouleau, G. Garnier, A. El-Balat, C. Zamagni, C. Martin-Lorente, E. Pujade-Lauraine, A. Fievet, I. L. Ray-Coquard
Summary: The addition of maintenance olaparib to bevacizumab in high-grade ovarian cancer patients has shown prolonged progression-free survival. The location of the BRCA1/BRCA2 mutation does not affect the benefit from olaparib and bevacizumab.
ANNALS OF ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Taylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Kamal Kant Sahu, Divyam Goel, Benjamin L. Maughan, Deepika Sirohi, Neeraj Agarwal, Umang Swami
Summary: This study found a high level of concordance between tissue and blood for BRCA mutations in patients with metastatic prostate cancer. Testing cell-free DNA in blood can provide reliable information on BRCA mutational status when solid tissue sequencing is unavailable. The occurrence of new BRCA mutations later in the disease course is rare.
Article
Oncology
Dianjie Li, Hong Gao, Wanting Zheng, Chunzhu Jin, Yuxin Huang, Shilei Pan
Summary: Fetal cervical teratoma is a rare congenital tumor that affects the survival of the patients. This article reports a case of this disease, in which histology and genetic sequencing techniques were used to analyze the tumor and identified a copy number variation related to chromosome 14q24.1-q24.3. Ultrasound and MRI can be used as reliable diagnostic tools, and surgical intervention with placental support can improve the chances of newborn survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Antoine Simoneau, Rosalinda Xiong, Lee Zou
Summary: PARP inhibitor (PARPi) generates DNA double-strand breaks (DSBs) predominantly in a trans cell cycle manner by inducing single-stranded DNA (ssDNA) gaps during the first S phase after exposure. BRCA1/2-deficient cells are unable to effectively repair DSBs, resulting in the unique efficacy of PARPi in these cells.
GENES & DEVELOPMENT
(2021)
Article
Oncology
Ning Li, Hualei Bu, Jihong Liu, Jianqing Zhu, Qi Zhou, Li Wang, Rutie Yin, Xiaohua Wu, Shuzhong Yao, Kangsheng Gu, Hui Zhang, Guiling Li, Hongming Pan, Qiang Wu, Ruifang An, Xinfeng Yang, Yaping Zhu, Xiaoping Wan, Wei Duan, Jianping Xiong, Hongyan Guo, Ge Lou, Jing Wang, Wenjing Hu, Xin Zhang, Yuanguang Meng, Ben Zhang, Yuting Wang, Quanren Wang, Lingying Wu
Summary: The study demonstrated that fluzoparib has promising antitumor activity and an acceptable safety profile in patients with germline BRCA1/2-mutated, platinum-sensitive relapsed ovarian cancer, with high objective response rates and prolonged progression-free survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Nozomu Yanaihara, Yuki Yoshino, Daito Noguchi, Junya Tabata, Masataka Takenaka, Yasushi Iida, Misato Saito, Satoshi Yanagida, Masami Iwamoto, Takako Kiyokawa, Natsuko Chiba, Aikou Okamoto
Summary: This study aimed to investigate the cellular effects of paclitaxel (PTX) on HR-proficient (HRP) ovarian cancer cells and evaluate the therapeutic application of PTX in combination with PARPi. The results demonstrated that PTX suppressed CDK1 expression, leading to impaired BRCA1 phosphorylation and increased sensitivity to PARPi. Clinical evidence supported the potential of PTX in combination with PARPi as a novel treatment strategy for HRP ovarian cancer.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
D. Hodgson, Z. Lai, S. Dearden, J. C. Barrett, E. A. Harrington, K. Timms, J. Lanchbury, W. Wu, A. Allen, E. Senkus, S. M. Domchek, M. Robson
Summary: In this study, testing for BRCA1 and/or BRCA2 mutations in tumor tissue was found to be an additional route to inform treatment selection for PARP inhibition in patients with HER2-negative metastatic breast cancer. The high concordance between germline and tumor tissue testing, as well as the common occurrence of gsLOH, suggests biallelic inactivation in metastatic breast cancer. Furthermore, the efficacy of Olaparib was observed irrespective of gsLOH status or HRD score, indicating that additional tissue testing may not be necessary for treatment selection in these patients.
ANNALS OF ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Akiyoshi Kasuga, Takeshi Okamoto, Shohei Udagawa, Chinatsu Mori, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Tsuyoshi Takeda, Masato Matsuyama, Takashi Sasaki, Masato Ozaka, Arisa Ueki, Naoki Sasahira
Summary: Hereditary pancreatic cancers are mainly caused by inherited genes, with familial pancreatic cancer accounting for a portion of cases. Known susceptibility genes include BRCA1 and BRCA2. Targeted medications have been developed for these mutations. Additionally, certain features are associated with homologous recombination deficiency and sensitivity to targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Health Care Sciences & Services
Christina T. Grech, Dietmar Pils, Stefanie Aust, Christoph Grimm, Stephan Polterauer, Alexander Reinthaller, Leonhard Muellauer, Theresa Reischer, Christine Bekos
Summary: The study found that high cVAF was significantly associated with better response to PARP inhibitors in ovarian cancer patients in terms of longer progression-free survival.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Multidisciplinary Sciences
John J. Krais, Yifan Wang, Pooja Patel, Jayati Basu, Andrea J. Bernhardy, Neil Johnson
Summary: This study reveals the role of RNF168 in localizing the BRCA1-P complex to DNA damage, recruiting PALB2 through BARD1-BRCA1 during homologous recombination repair. These molecular interactions connect DNA damage signaling and HR repair machinery.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Di Zhang, Bijay Singh, Jessica Moerland, Owen Mitchell, Lizbeth Lockwood, Sarah Carapellucci, Srinivas Sridhar, Karen T. Liby
Summary: The study demonstrated that localized delivery of a PARP inhibitor through implants significantly decreased the incidence of mammary hyperplasia in BRCA1-deficient mice. The novel formulation was not only effective in reducing proliferation and increasing DNA damage, but also better tolerated compared to oral administration.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Dong Wang, Li Song, Li Shen, Kaihui Zhang, Yuqiang Lv, Min Gao, Jian Ma, Ya Wan, Zhongtao Gai, Yi Liu
Summary: This study identified ANK1 and SPTB as the most frequently mutated genes in Chinese patients with HS, with higher mutation frequency of ANK1 in specific exons. Missense mutations were more common in SLC4A1, while most mutations in ANK1 and SPTB were nonsense or frameshift mutations. The study expanded the mutation spectrum of ANK1 and SPTB, providing insights into the mutational characteristics of causative genes in Chinese HS patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Rossella Bruno, Elisa Sensi, Cristiana Lupi, Mirella Giordano, Laura Bernardini, Caterina Vivaldi, Lorenzo Fornaro, Enrico Vasile, Daniela Campani, Gabriella Fontanini
Summary: PDAC is an aggressive cancer often diagnosed in advanced stages with limited treatment options. Olaparib, a PARP inhibitor, is approved for maintenance therapy in PDAC patients with BRCA1/2 mutations. Testing for BRCA1/2 mutations in pancreatic tumor tissues is feasible on small biopsies.
Article
Oncology
Elzbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conte, Seock-Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark Robson, Nadine Tung
Summary: In the primary analysis of the phase III OlympiAD trial, olaparib significantly extended the progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer compared to chemotherapy treatment. Subgroup analyses confirmed the consistent benefit of olaparib across various patient subgroups.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Pediatrics
D. Diallo, A. Hochart, M. Lagree, B. Dervaux, A. Martinot, F. Dubos
ARCHIVES DE PEDIATRIE
(2019)
Review
Oncology
Francois Bertucci, Anne-Gaelle Le Corroller-Soriano, Audrey Monneur, Sylvain Fluzin, Patrice Viens, Dominique Maraninchi, Anthony Goncalves
BULLETIN DU CANCER
(2020)
Article
Biophysics
Didier Blaise, Sarah Calvin, Sarah Cuvelier, Patrick Ben Soussan, Charlene Villaron, Pierre Dantin, Patrice Viens
BONE MARROW TRANSPLANTATION
(2020)
Article
Oncology
Francois Bertucci, Charlotte Rypens, Pascal Finetti, Arnaud Guille, Jose Adelaide, Audrey Monneur, Nadine Carbuccia, Severine Garnier, Piet Dirix, Anthony Goncalves, Peter Vermeulen, Bisrat G. Debeb, Xiaoping Wang, Luc Dirix, Naoto T. Ueno, Patrice Viens, Massimo Cristofanilli, Max Chaffanet, Daniel Birnbaum, Steven Van Laere
MOLECULAR ONCOLOGY
(2020)
Article
Medicine, Research & Experimental
Caroline Gronnier, Cecile Chambrier, Alain Duhamel, Benoit Dervaux, Denis Collet, Delphine Vaudoyer, Jean-Marc Regimbeau, Jacques Jougon, Jeremie Thereaux, Gil Lebreton, Julie Veziant, Alain Valverde, Pablo Ortega-Deballon, Francois Pattou, Muriel Mathonnet, Julie Perinel, Laura Beyer-Berjot, David Fuks, Philippe Rouanet, Jeremie H. Lefevre, Pierre Cattan, Sophie Deguelte, Bernard Meunier, Jean-Jacques Tuech, Patrick Pessaux, Nicolas Carrere, Ephrem Salame, Eleonor Benaim, Bertrand Dousset, Simon Msika, Christophe Mariette, Guillaume Piessen
Article
Surgery
Maxime Dubosq, Yann Goueffic, Alain Duhamel, Fanette Denies, Benoit Dervaux, Gilles Goyault, Jonathan Sobocinski
Summary: The study aims to evaluate the potential benefit for patients on the result of endovascular revascularization of long occlusive femoropopliteal lesion at 12 months when using intraoperative OCT control.
ANNALS OF VASCULAR SURGERY
(2021)
Article
Surgery
Robert Caiazzo, Julien Branche, Violeta Raverdy, Sebastien Czernichow, Claire Carette, Maud Robert, Emmanuel Disse, Marc Barthet, Bertrand Cariou, Simon Msika, Helene Behal, Fanette Denies, Benoit Dervaux, Alain Duhamel, Helene Verkindt, Francois Pattou
Article
Health Care Sciences & Services
Vincent Vandewalle, Alexandre Caron, Coralie Delettrez, Renaud Perichon, Sylvia Pelayo, Alain Duhamel, Benoit Dervaux
BMC MEDICAL RESEARCH METHODOLOGY
(2020)
Article
Economics
Alexandre Caron, Vincent Vandewalle, Romaric Marcilly, Jessica Rochat, Benoit Dervaux
Summary: A value-of-information analysis method was developed to estimate the sample size for usability testing of medical devices from the perspective of the device manufacturer. The results indicate that our method is highly suitable for sample size estimation in usability testing before market access of medical devices.
Article
Public, Environmental & Occupational Health
Melanie Drolet, Aurelie Godbout, Myrto Mondor, Guillaume Beraud, Lea Drolet-Roy, Philippe Lemieux-Mellouki, Alexandre Bureau, Eric Demers, Marie-Claude Boily, Chantal Sauvageau, Gaston De Serres, Niel Hens, Philippe Beutels, Benoit Dervaux, Marc Brisson
Summary: A study in Quebec, Canada found that social contacts significantly decreased since the beginning of the COVID-19 pandemic, which likely helped mitigate the spread of the virus. The study showed that public health measures such as school closures and gathering restrictions had an impact on social contacts.
Article
Immunology
Zhuxin Mao, Xiao Li, Ana Dacosta-Urbieta, Marie-Noelle Billard, Joanne Wildenbeest, Koos Korsten, Federico Martinon-Torres, Terho Heikkinen, Steve Cunningham, Matthew D. Snape, Hannah Robinson, Andrew J. Pollard, Maarten Postma, Benoit Dervaux, Niel Hens, Louis Bont, Joke Bilcke, Philippe Beutels
Summary: The study aimed to evaluate the costs and health-related quality of life (HRQoL) effects associated with respiratory syncytial virus (RSV) infection in infants and their caregivers. The results showed that RSV infection resulted in significant cost burden and loss of HRQoL.
Article
Pediatrics
Benoit Dervaux, Marine Van Berleere, Xavier Lenne, Marine Wyckaert, Francois Dubos, RESCEU Investigators
Summary: This study compared hospitalization costs for RSV-positive and RSV-negative bronchiolitis in a French university medical center from 2010 to 2015. It found that RSV-positive cases required more oxygen therapy and respiratory support, but the significant effect on costs weakened in the multivariate model.
FRONTIERS IN PEDIATRICS
(2023)
Meeting Abstract
Clinical Neurology
S. Bayen, C. Moreau, N. Carriere, J. P. Pruvo, M. Bayen, F. Richard, B. Dervaux, L. Defebvre, D. Devos
MOVEMENT DISORDERS
(2020)
Meeting Abstract
Oncology
V. D'Hondt, J. -L. Canon, L. Roca, C. Levy, J. -Y. Pierga, F. Le Du, M. Campone, I. Desmoulins, P. Viens, M. Debled, J. -M. Ferrero, D. Serin, A. -C. Hardy Bessard, E. Brain, N. Dohollou, H. Orfeuvre, J. Lemonnier, H. Roche, S. Delaloge, F. Dalenc
ANNALS OF ONCOLOGY
(2019)
Meeting Abstract
Oncology
A. Monneur, F. Bertucci, A. Lardy-Cleaud, P. Augereau, M. Debled, C. Levy, M. A. Mouret-Reynier, B. Coudert, A. Mailliez, T. Bachelot, J-M Ferrero, S. Guiu, L. Uwer, M. Campone, P. Cottu, C. Jouannaud, T. De la Motte Rouge, M. Leheurteur, T. Petit, B. Pistilli, F. Dalenc, G. Simon, M. Robain, P. Viens, F. Lerebours, A. Goncalves